MX2017008541A - Anticuerpos biespecificos contra calicreina y factor xii del plasma. - Google Patents

Anticuerpos biespecificos contra calicreina y factor xii del plasma.

Info

Publication number
MX2017008541A
MX2017008541A MX2017008541A MX2017008541A MX2017008541A MX 2017008541 A MX2017008541 A MX 2017008541A MX 2017008541 A MX2017008541 A MX 2017008541A MX 2017008541 A MX2017008541 A MX 2017008541A MX 2017008541 A MX2017008541 A MX 2017008541A
Authority
MX
Mexico
Prior art keywords
light chain
plasma kallikrein
factor xii
bispecific antibodies
heavy chain
Prior art date
Application number
MX2017008541A
Other languages
English (en)
Spanish (es)
Inventor
A Kenniston Jon
Adelman Burt
R Comeau Stephen
Nixon Andrew
KASTRAPELI Niksa
P Conley Gregory
MASON Shauna
P Lindberg Allison
Kopacz Kristopher
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of MX2017008541A publication Critical patent/MX2017008541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2017008541A 2015-01-02 2015-12-31 Anticuerpos biespecificos contra calicreina y factor xii del plasma. MX2017008541A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562099236P 2015-01-02 2015-01-02
US201562200363P 2015-08-03 2015-08-03
US201562261609P 2015-12-01 2015-12-01
PCT/US2015/068238 WO2016109774A1 (en) 2015-01-02 2015-12-31 Bispecific antibodies against plasma kallikrein and factor xii

Publications (1)

Publication Number Publication Date
MX2017008541A true MX2017008541A (es) 2017-12-04

Family

ID=56285069

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008541A MX2017008541A (es) 2015-01-02 2015-12-31 Anticuerpos biespecificos contra calicreina y factor xii del plasma.
MX2024000317A MX2024000317A (es) 2015-01-02 2017-06-26 Anticuerpos biespecificos contra calicreina y factor xii del plasma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024000317A MX2024000317A (es) 2015-01-02 2017-06-26 Anticuerpos biespecificos contra calicreina y factor xii del plasma.

Country Status (13)

Country Link
US (2) US11390687B2 (enExample)
EP (2) EP4670785A3 (enExample)
JP (4) JP6744313B2 (enExample)
KR (1) KR102670705B1 (enExample)
CN (2) CN107405399B (enExample)
AU (2) AU2015373910B2 (enExample)
CA (1) CA2972800A1 (enExample)
CO (1) CO2017007123A2 (enExample)
EA (1) EA201791527A1 (enExample)
IL (2) IL298086B2 (enExample)
MX (2) MX2017008541A (enExample)
NZ (1) NZ771568A (enExample)
WO (1) WO2016109774A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
JP7068160B2 (ja) * 2015-07-21 2022-05-16 武田薬品工業株式会社 第ＸＩＩａ因子のモノクローナル抗体阻害剤
CN109716129B (zh) 2016-09-16 2023-10-03 武田药品工业株式会社 用于遗传性血管性水肿的rna生物标记
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
US20200216544A1 (en) * 2017-08-16 2020-07-09 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1
AU2018350992A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
EP3737949A1 (en) * 2018-01-12 2020-11-18 Genzyme Corporation Methods for the quantitation of polypeptides
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (ja) * 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
WO2019235627A1 (ja) * 2018-06-08 2019-12-12 株式会社モダリス 改変されたＣａｓ９タンパク質及びその用途
JP2021530989A (ja) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US20210206859A1 (en) * 2018-08-08 2021-07-08 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
EP3833392A4 (en) * 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EP3833385A4 (en) * 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
KR20210082189A (ko) * 2018-10-24 2021-07-02 샤이어-엔피에스 파마슈티칼즈, 인크. Glp-2 융합 폴리펩티드 및 위장 병태를 치료 및 예방하기 위한 용도
TWI894157B (zh) * 2019-07-26 2025-08-21 美商健生生物科技公司 包含血管舒緩素相關肽酶２抗原結合域之蛋白質及其用途
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
EP4236974A2 (en) * 2020-10-29 2023-09-06 RegenxBio Inc. Vectorized factor xii antibodies and administration thereof
WO2022156798A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
WO2022156799A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
JP7642857B2 (ja) * 2021-04-22 2025-03-10 広東菲鵬制▲薬▼股▲ふん▼有限公司 二重特異性多機能性融合ポリペプチド
WO2024238407A2 (en) * 2023-05-12 2024-11-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
EP0737750B1 (en) 1989-03-21 2003-05-14 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0711829A3 (en) 1993-09-15 1997-07-09 Viagene Inc Recombinant alphavirus vector
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
JP3002702B2 (ja) 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド 活性物質の制御放出を有する小胞
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
CA2364484A1 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
CN101255196A (zh) * 2002-06-28 2008-09-03 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
ES2407965T3 (es) 2004-12-23 2013-06-17 Csl Behring Gmbh Prevención de la formación y/o estabilización de trombos
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
US7932021B2 (en) 2005-07-28 2011-04-26 American Diagnostica, Inc. Lupus anticoagulant testing
GB0607515D0 (en) 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
TWI496582B (zh) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
LT2373691T (lt) 2008-12-18 2019-05-27 Oregon Health & Science University Anti-fxi antikūnai ir jų panaudojimo būdai
ES2688093T3 (es) 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
EP2548892A1 (en) * 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
JP6253578B2 (ja) * 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
JP5653860B2 (ja) 2011-07-28 2015-01-14 富士フイルム株式会社 管壁の硬度測定方法および装置
EP2765192A4 (en) * 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGENBINDING MOLECULE FOR PREPARING A SPACE BETWEEN A PLASMA AND AN ANTIGEN WITH A SACCHARIDE CHAIN RECEPTOR BINDING DOMAIN
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
US20140038204A1 (en) * 2012-07-31 2014-02-06 Baxter Healthcare S.A. Selective measurement of active human protease coagulation factors
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
HUE044285T2 (hu) 2013-01-20 2019-10-28 Dyax Corp PKal-mediálta rendellenességek értékelése, vizsgálata és kezelése
JP2016513682A (ja) * 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
JP2017501968A (ja) * 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
JP7068160B2 (ja) * 2015-07-21 2022-05-16 武田薬品工業株式会社 第ＸＩＩａ因子のモノクローナル抗体阻害剤
EP3263803B1 (en) 2016-06-30 2019-08-14 ABB Schweiz AG Substation

Also Published As

Publication number Publication date
EP3240570C0 (en) 2025-09-24
KR102670705B1 (ko) 2024-05-31
JP7003347B2 (ja) 2022-02-04
JP2022023038A (ja) 2022-02-07
IL298086A (en) 2023-01-01
IL298086B1 (en) 2024-07-01
IL253180B2 (en) 2023-04-01
KR20240091031A (ko) 2024-06-21
JP7241827B2 (ja) 2023-03-17
US12240918B2 (en) 2025-03-04
CN114316061B (zh) 2024-11-01
AU2022201076A1 (en) 2022-03-10
CN107405399A (zh) 2017-11-28
AU2015373910B2 (en) 2021-11-18
IL298086B2 (en) 2024-11-01
JP2018502572A (ja) 2018-02-01
IL253180B (en) 2022-12-01
JP2020186248A (ja) 2020-11-19
IL253180A0 (en) 2017-08-31
CA2972800A1 (en) 2016-07-07
CO2017007123A2 (es) 2017-12-15
BR112017014308A2 (pt) 2018-03-06
EA201791527A1 (ru) 2017-12-29
CN114316061A (zh) 2022-04-12
JP2023065659A (ja) 2023-05-12
EP4670785A2 (en) 2025-12-31
US20230117565A1 (en) 2023-04-20
AU2015373910A1 (en) 2017-07-27
CN107405399B (zh) 2022-02-08
EP4670785A3 (en) 2026-04-01
EP3240570B1 (en) 2025-09-24
JP6744313B2 (ja) 2020-08-26
EP3240570A1 (en) 2017-11-08
JP7635285B2 (ja) 2025-02-25
US20180118851A1 (en) 2018-05-03
NZ771568A (en) 2024-11-29
US11390687B2 (en) 2022-07-19
KR20170118058A (ko) 2017-10-24
AU2022201076B2 (en) 2025-05-15
MX2024000317A (es) 2024-01-25
NZ733580A (en) 2024-02-23
EP3240570A4 (en) 2018-08-08
WO2016109774A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
MX2024000317A (es) Anticuerpos biespecificos contra calicreina y factor xii del plasma.
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
GEAP202215170A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EA201990894A9 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
CR20190435A (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
PY1829572A (es) Dominios de unión a antígeno humanizados y métodos de uso
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
ZA202208337B (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
MX2023006511A (es) Un anticuerpo monoclonal inhibidor del factor xiia.
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
MX2019011585A (es) Anticuerpos miltiespecificos estables.
IL285308A (en) Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
ZA202205288B (en) Humanized antibody and method for using the same
EA201990253A1 (ru) Гуманизированные антитела против s100a9 и их применение
MX2019005552A (es) Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
IL280745A (en) Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen-binding molecules that bind FCER1A and CD3, and uses thereof
MX2019007019A (es) Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
BR112018076247A2 (pt) anticorpos monoclonais quiméricos e humanizados para cd81
WO2020033926A3 (en) Antibodies that bind cd277 and uses thereof
ZA202106551B (en) Anti-bag2 antibody and methods of treating cancer